CervoMed Presents Interim Neflamapimod Biomarker Data at CTAD 2026
CervoMed said interim data show neflamapimod reduces a neurodegeneration biomarker in nonfluent variant primary progressive aphasia.
CervoMed said interim data show neflamapimod reduces a neurodegeneration biomarker in nonfluent variant primary progressive aphasia.